Diet Intervention in Food Sensitive Patients With IgA Nephropathy
NCT ID: NCT01203007
Last Updated: 2010-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2010-09-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tailored diet
Tailored diet according to demonstrated food sensitivity
Tailored diet
Tailored diet according to demonstrated food sensitivity, 6 months
Low-antigen content (LAC) diet
Low-antigen content diet
Low antigen content diet
Low-antigen content diet for one month
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tailored diet
Tailored diet according to demonstrated food sensitivity, 6 months
Low antigen content diet
Low-antigen content diet for one month
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* IgA nephropathy (IgAN), verified by biopsy
* Proteinuria \> 1 g/24 h
* Having signed informed consent form
Exclusion Criteria
* Patients with celiac disease
* Introduction of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARB) during the last three months prior to inclusion
* Patients treated with immunosuppressive or systemic corticosteroid drugs within the last twelve months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Linkoeping
OTHER
Haukeland University Hospital
OTHER
Smerud Medical Research International AS
OTHER
Uppsala University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Uppsala University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hilde K Smerud, MScPharm
Role: STUDY_DIRECTOR
Uppsala University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Haukeland University Hospital
Bergen, , Norway
Linköping University Hospital
Linköping, , Sweden
Uppsala University Hospital
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMR-2259
Identifier Type: -
Identifier Source: org_study_id